SITC Resource Library

2020-2021 Advances in Cancer Immunotherapy™ Webinar Series - Clinical Updates from ESMO Immuno-Oncology Congress 2020 - Recorded Webinar and Presentation Slides 

07-08-2021 12:16

On July 16, 2021, leading experts in cancer immunotherapy discussed the latest advances in cancer immunotherapy emerging from ESMO Immuno-Oncology Virtual Congress 2020. The recorded webinar and presentation slides are available below.

Indicates this content is not available on-demand. 

Webinar Faculty:

  • Moderator: Paolo A. Ascierto, MD – Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale'
  • Presenters:
    • Sunandana Chandra, MD, MS – Northwestern University
    • Julia Katharina Schwarze, MD, MSc – University Hospital Brussels
Joseph Sacco, MBChB, MSc, MRCP, PhD – The Clatterbridge Cancer Centre

Featured Presentations:

  • A Phase (ph) 2, Multi-Center Study of the Safety and Efficacy of tebentafusp (tebe) (IMCgp100) in Patients (pts) with Metastatic Uveal Melanoma (mUM) - Presenter: Joseph Sacco, MBChB, MSc, MRCP, PhD
  • A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma - Julia Katharina Schwarze, MD, MSc
  • Additional clinical abstracts of interest from ESMO Immuno-Oncology Congress 2020 will be presented by Sunandana Chandra, MD, MS

Please note that the on-demand webinar is not available for continuing education credits.

Statistics
0 Favorited
142 Views
3 Files
0 Shares
30 Downloads
Attachment(s)
mp4 file
2020-2021 Advances in Cancer Immunotherapy™ Webinar Serie...   626.09 MB   1 version
Uploaded - 09-15-2021
Moderator: Paolo A. Ascierto, MD – Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale'; Presenters: Sunandana Chandra, MD, MS – Northwestern University, Julia Katharina Schwarze, MD, MSc – University Hospital Brussels; Date: July 16, 2021
pdf file
Julia Katharina Schwarze - Slides   1.52 MB   1 version
Uploaded - 09-15-2021
A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma; Presenter: Julia Katharina Schwarze, MD, MSc – University Hospital Brussels; Date July 16, 2021
pdf file
Sunandana Chandra - Slides   1.48 MB   1 version
Uploaded - 09-15-2021
Additional clinical abstracts of interest from ESMO Immuno-Oncology Congress 2020; Presenter: Sunandana Chandra, MD, MS – Northwestern University; Date July 16, 2021

Related Entries and Links

No Related Resource entered.